Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac N.V. (Nasdaq: CVAC) has announced a follow-on public offering of 5 million common shares priced at $90.00 each, aiming for gross proceeds of approximately $450 million. The underwriters have an option to purchase an additional 750,000 shares within 30 days. The offering will close on February 1, 2021, pending customary conditions. BofA Securities, Jefferies, and Evercore ISI are the joint book-running managers. This follows a registration declaration by the SEC on January 27, 2021.
CureVac (NASDAQ:CVAC) announced a public offering of 5,000,000 common shares, with a potential additional 750,000 shares from underwriters. The offering aims to raise capital for its mRNA technology development, focusing on vaccines and therapies. Joint book-running managers include BofA Securities, Jefferies, and Evercore ISI. The registration statement is pending approval by the SEC, and all shares will be offered by CureVac. This move reflects the company's ongoing efforts to expand its clinical pipeline.
CureVac N.V. (Nasdaq: CVAC) announced promising preclinical data for its COVID-19 vaccine candidate, CVnCoV, highlighting strong antibody and T cell responses in non-human primates. Animals vaccinated with 8μg of CVnCoV displayed full lung protection against SARS-CoV-2, reinforcing the vaccine's immunogenicity and efficacy at lower doses than those used in ongoing Phase 2b/3 trials. The findings support the continuation of clinical studies and suggest potential for broader immunization against COVID-19.
Bayer has established a collaboration and services agreement with CureVac (NASDAQ:CVAC) to support the development and supply of the COVID-19 vaccine candidate CVnCoV. Bayer will utilize its expertise and infrastructure in critical areas such as clinical operations and regulatory affairs, aiming to facilitate the supply of several hundred million doses globally upon regulatory approval. CureVac will retain Marketing Authorization Holder status, while Bayer will assist with operations in the EU and select markets. This partnership is expected to enhance vaccine accessibility amid the ongoing pandemic.
CureVac N.V. (Nasdaq: CVAC) announced the enrollment of the first participant in its Phase 2b/3 study for its mRNA vaccine candidate, CVnCoV, targeting COVID-19. This pivotal trial, named HERALD, plans to enroll over 35,000 participants across Europe and Latin America, assessing vaccine safety and efficacy at a 12 µg dose. The study aims to prevent confirmed COVID-19 cases and includes a long-term monitoring phase for safety and efficacy. Previous trials showed promising immunogenicity and tolerability for CVnCoV.
CureVac (NASDAQ:CVAC) appointed Antony Blanc, PhD, as Chief Business Officer and Chief Commercial Officer, effective immediately. Blanc brings extensive experience in biotech and vaccines, previously serving roles at McKinsey & Company and GSK Vaccines. His expertise in RNA research is expected to enhance CureVac's business development and growth. The company is advancing its mRNA-based COVID-19 vaccine, CVnCoV, with promising Phase 1 interim data indicating strong antibody responses. CureVac is also expanding manufacturing capacities to prepare for commercial supply.
CureVac (NASDAQ: CVAC) reported promising interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV, demonstrating strong antibody responses and T-cell activation. The company secured an agreement with the European Commission to supply 225 million doses, with an option for 180 million more. CureVac reported a cash position of €892 million and revenues of €5.2 million for Q3 2020, marking a 371% increase year-over-year. The company plans to initiate a pivotal Phase 2b/3 trial shortly, aiming to expand its vaccine capabilities and address the ongoing pandemic.
CureVac N.V. (Nasdaq:CVAC) will report its financial results and business updates for Q3 and the first nine months of 2020 on November 30, 2020. A conference call and webcast will occur at 4:00 p.m. CET / 10:00 a.m. EST with details provided for participation. This follows the company's IPO in August 2020, marking its entry into the public market. CureVac focuses on mRNA technology, with a pipeline in vaccines, cancer therapies, and rare diseases. The company has over 500 employees and is headquartered in Tübingen, Germany.
CureVac N.V. (NASDAQ:CVAC) has announced plans to expand its manufacturing capabilities for the COVID-19 vaccine candidate, CVnCoV, aiming for up to 300 million doses in 2021 and 600 million doses in 2022. This initiative involves building a European vaccine manufacturing network with experienced partners to mitigate supply chain risks. The company is in the process of finalizing technology transfers and establishing partnerships with various CDMO firms across Europe, enhancing production resilience.
CureVac (Nasdaq:CVAC) announced that the European Commission will authorize an Advanced Purchase Agreement for its mRNA-based COVID-19 vaccine candidate, CVnCoV. The contract encompasses 225 million initial doses, with an option for an additional 180 million doses. An upfront payment will support advanced clinical development and ramp-up of manufacturing capabilities. CVnCoV is undergoing pivotal Phase 2b/3 clinical trials, following promising Phase 1 data indicating strong immune responses. CureVac aims to provide equitable access to its vaccine globally.
